Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Novo Nordisk's weight loss candidate in question ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

CDMOs: Challenges & Opportunities in a Big Year of Change. Gil Roth, President of the Pharma & Biopharma Outsourcing Association, shared his insights in the CPHI Annual Report 202 ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

The acquisition was announced on Monday with James Walker, CEO of Agostini’s Pharmaceutical Group, presents at MDJL’s Carifta ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...